The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)

In patients with metastatic prostate cancer (PCa) who receive androgen deprivation therapy (ADT), the sensitivity to castration will eventually disappear due to the selection of castration-refractory clones. This will lead to the stage of metastatic castration-refractory prostate can-cer (mCRPC), which is incurable and results in a median overall survival of 2-3 years. Treatment options for patients with mCRPC include several systemic agents, such as andro-gen receptor-targeted agents (ARTA), chemotherapy (docetaxel, cabazitaxel) and bone-targeting agents (radium- 223). Clinical progression a

Trial Details

NCT ID
NCT07038304
Phase
PHASE2
Sponsor
University Medical Center Groningen
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Metastasis directed radiotherapy
Locations (sample)
  • Groningen, Netherlands|53.21917,6.56667
  • Nijmegen, Netherlands|51.8425,5.85278

Key Eligibility Criteria

  • Adenocarcinoma of the prostate.
  • mCRPC setting, with testosterone level \< 50 ng/dl or 1.7 nmol/l.
  • Oligoprogressive disease diagnosed on PSMAscan; defined as the progression of pre-existing metastatic disease, and/or the appearance of new metasta…
  • Patients currently treated with ADT, whether combined with another systemic treatment such as ARTA, chemotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →